Angioplasty-eligible patients assigned to year-long clopidogrel treatment appear to have significantly reduced rates of coronary and stroke events, researchers reported here November 18 at the 2002 Scientific Sessions of the American Heart Association (AHA). During a late-breaker oral presentation, doctors reported a 27 percent reduction in the combined primary end point of death, heart attack or stroke in the intent-to-treat population of 2,118 people.
The reduction achieved statistical significance at the p=0.02 level. Steven Steinhubl, MD, associate professor of medicine at University of North Carolina, in Chapel Hill, North Carolina, United States, and his colleagues recruited patients in 99 centers in the United States and Canada for the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!